MBX Biosciences, Inc. MBX
Regular-session close
After hours · Nov 20, 4:01 PM ET
- YTD
- +57.10%
- 1 year
- +83.31%
Held by funds
113 US ETFs and mutual funds hold MBX · largest positions
- FBTTX 2.04% of fund $47.93M
- VTI 0.00% of fund $47.58M
- IWM 0.06% of fund $43.32M
- FDSCX 0.56% of fund $41.56M
- FSPHX 0.60% of fund $41.03M
- FIDGX 0.29% of fund $25.65M
- FSSNX 0.06% of fund $20.94M
- FHCIX 0.60% of fund $20.22M
- NJM 0.03% of fund $20.20M
- FFIDX 0.21% of fund $19.78M
- VXF 0.02% of fund $18.98M
- FBIOX 0.26% of fund $15.72M
- IWO 0.12% of fund $15.58M
- IBB 0.12% of fund $12.76M
- FNITX 0.04% of fund $12.04M
- FSCRX 0.53% of fund $11.72M
- VTWO 0.06% of fund $10.20M
- FBALX 0.01% of fund $10.20M
- FBGRX 0.01% of fund $9.97M
- XPH 1.80% of fund $9.14M
Ownership
Top institutional holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.84% | 7,368,420 | 365.11M | Sep 29, 2026 |
| Frazier Life Sciences Management, L.P. | 13.40% | 6,652,013 | 329.61M | Sep 29, 2026 |
| Wellington Management Group, LLP | 10.40% | 5,164,535 | 255.90M | Sep 29, 2026 |
| Paradigm Biocapital Advisors LP | 7.60% | 3,772,885 | 186.95M | Sep 29, 2026 |
| NEA Management Company, LLC | 7.28% | 3,614,486 | 179.10M | Sep 29, 2026 |
| Blackrock Inc. | 6.99% | 3,473,447 | 172.11M | Sep 29, 2026 |
Top mutual fund holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.29% | 1,135,375 | 56.26M | Jun 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.76% | 873,492 | 43.28M | Jun 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.65% | 817,600 | 40.51M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.62% | 805,557 | 39.92M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.41% | 700,000 | 34.68M | Sep 29, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 1.36% | 674,700 | 33.43M | Aug 30, 2026 |
Included in Plus and up
Sign in to see Institutional ownership
How much funds own from their 13F filings, quarter by quarter, and the largest holders.
Free with an account
Sign in to see Insider activity
Two years of insider buying and selling by month, marked on the price.
Included in Plus and up
Sign in to see Congress trading
Every stock trade disclosed by members of the US Senate and House.
Leadership team
Who runs MBX, and what each was last paid
Steven L. Hoerter, Executive Chairperson, CEO & PresidentAverage age 62
| Name | Title | Pay | Age |
|---|---|---|---|
| Steven L. Hoerter | Executive Chairperson, CEO & President | $40.5K | 55 |
| Salomon Azoulay | Chief Medical Officer | $735K | 68 |
| John W. Smither | Chief Financial Officer | $642K | 73 |
| Andreas Moraitis | Senior Vice President of Clinical Development | — | — |
| Karen Basbaum | Chief Business Officer | — | — |
| Michelle Graham | Chief Human Resources Officer | — | 59 |
| Mark Hope | Chief Regulatory & Quality Officer | — | — |
| Mark R. Soued | Chief Commercial Officer | — | — |
| Pete De Spain | Senior Vice President of Investor Relations & Corporate Communications | — | — |
| Jeffrey Held | Chief Legal Officer | — | 57 |
| Chatan Charan | Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls | — | — |
| Michael A. Dorato DABT | Sr. Vice President of Discovery & Non-Clinical Development | — | — |
Pay is the latest total FMP has for each person (salary, bonus, stock and other awards) and can lag the newest proxy statement. Source: Financial Modeling Prep, from the company’s SEC filings.
Free with an account
Sign in to see CEO compensation
What the chief executive was paid each year, by salary, bonus and stock, beside the company's earnings.
Free with an account
Sign in to see Board of directors
Who sits on the board, who chairs it, and how long each director has served.
Insiders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AZOULAY SALOMON M.D. | Officer | Sale | Nov 3, 2026 | 14,026 |
| BARTRAM RICHARD B | Chief Financial Officer | Stock Award(Grant) | Feb 1, 2026 | 15,000 |
| GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 17, 2025 | 0 |
| HAWRYLUK P KENT | Chief Executive Officer | Sale | May 5, 2026 | 1,214,440 |
| HERON PATRICK J | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 25, 2025 | 0 |
| HOERTER STEVEN L | Chief Executive Officer | Sale | Nov 9, 2026 | 98,045 |
